SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery

Élie Haddad, Brent R. Logan, Linda M. Griffith, Rebecca H. Buckley, Roberta Parrott, Susan E. Prockop, Trudy N. Small, Jessica Chaisson, Christopher C. Dvorak, Megan Murnane,

Blood · 2018 · 175 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

Key Points The genetic cause of SCID impacts on survival and immune reconstitution and should be considered in tailoring HCT for individual patients. Total and naive CD4+ cell counts in SCID patients 6 and 12 months post-HCT predict long-term survival and sustained immune reconstitution.

References

21